Literature DB >> 22375977

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22375977     DOI： 10.1056/NEJMe1115119

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

Review 2.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 3.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

4.  Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.

Authors:  Hélène F E Gleitz; Aurélien J F Dugourd; Nils B Leimkühler; Inge A M Snoeren; Stijn N R Fuchs; Sylvia Menzel; Susanne Ziegler; Nicolaus Kröger; Ioanna Triviai; Guntram Büsche; Hans Kreipe; Bella Banjanin; Jessica E Pritchard; Remco Hoogenboezem; Eric M Bindels; Neele Schumacher; Stefan Rose-John; Shannon Elf; Julio Saez-Rodriguez; Rafael Kramann; Rebekka K Schneider
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

5.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

Review 6.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

7.  β-Arrestin2 mediates progression of murine primary myelofibrosis.

Authors:  Lindsay Am Rein; James W Wisler; Jihee Kim; Barbara Theriot; LiYin Huang; Trevor Price; Haeyoon Yang; Minyong Chen; Wei Chen; Dorothy Sipkins; Yuri Fedoriw; Julia Kl Walker; Richard T Premont; Robert J Lefkowitz
Journal:  JCI Insight       Date:  2017-12-21

Review 8.  Signal transduction in the chronic leukemias: implications for targeted therapies.

Authors:  Wesam Ahmed; Richard A Van Etten
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Authors:  Nicholas G Wysham; Donald R Sullivan; Gopal Allada
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.

Authors:  Markéta Bloomfield; Veronika Kanderová; Zuzana Paračková; Petra Vrabcová; Michael Svatoň; Eva Froňková; Martina Fejtková; Radana Zachová; Michal Rataj; Irena Zentsová; Tomáš Milota; Adam Klocperk; Tomáš Kalina; Anna Šedivá
Journal:  J Clin Immunol       Date:  2018-06-22       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.